Metformin as RenoProtector of Progressive Kidney Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 290 participants.

Also called NCT03831464

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 290 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03831464
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Belgium (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03831464. Randomized; quadruple masking; primary purpose treatment. Start 2019-11-05 (actual); primary completion 2024-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Metformin as RenoProtector of Progressive Kidney Disease
Acronym
RenoMet
Condition
Chronic Kidney Diseases
Intervention (Drug)
Metformin Hydrochloride
Intervention (Drug)
Placebo Oral Tablet
Lead sponsor
Universiteit Antwerpen (class: other)
Collaborator
University Hospital, Antwerp (class: other)

Record details

Record id
cardio:ct-nct03831464
Content hash
c47569f2ce51f43825a2ad2ad835b06b7ad1924b9cc96f4f80020853be2cf312